The correlation of XRCC-1 Gene Arg194Trp polymorphism with alcohol and tobacco substance user and with loco-regionally progressed squamous cell cancer of the larynx (LSCC) was assessed in this research study. The result of this research study is described herein. Material and methods: A tertiary hospital-based observational case-control research was carried out. DNA segregation and Genotype examination were done from the blood sample of the control group and cases to know the correlation between XRCC-1 gene polymorphism with loco-regionally progressed LSCC and with hazard factors tobacco and alcohol. Results: In the cases, the existence of DNA repair XRCC-1 gene polymorphic variants (Hetero CT and Mutant TT) was recognizable in contrary to the control group arm. The XRCC-1 gene polymorphic hetero (CT) genotype (O.R-1.96; 95% C.I: 1.23-3.13; P < 0.004) and mutant (TT) genotype variants (O.R-1.95; 95% C.I: 0.59-6.44; P = 0.27) was correlated with access hazard of loco-regionally progressed LSCC, and its statistically convincing for polymorphic hetero (CT) variant. The data were adapted for the age of the patients and control group, circadian alcohol intake, tobacco chewing habits, and the tobacco smoking habits during application of multivariate logistic regression. Its apparent that the hazard is amalgamated with hetero (CT) genotype variant (O.R-1.67; 95% C.I: 0.98-2.82; P = 0.05) and mutant (TT) genotype variant (O.R-1.62; 95% C.I: 0.88-2.78; P = 0.11) and its statistically convincing for polymorphic hetero (CT) genotype variant. Cases with the record of substance use (alcohol and tobacco) have an abundance of XRCC-1 hetero (CT) and mutant (TT) genotype variants in allegory to control group. Increased hazard is related with XRCC-1 hetero (CT) variant in smokers (
Background: Cancer has emerged as huge epidemic over past two decades. There is a declining trend in the incidence of cervical cancer in the western world on the contrary in India we have observed that this disease is a great menace to a women’s health and is showing rising trend. Within the country there is wide range of variation in demography and epidemiology. There is lack of published data available on epidemiology such as age, incidence, burden, compliance of patients having cervical cancer in Uttar Pradesh. Aims and Objectives: Current study aims to gather the evidence to understand the pattern of cervical cancer burden in the community and to find out the lacunae in the treatment delivery and receiving end. Materials and Methods: A retrospective study was conducted on patients of cancer cervix visiting OPD of department of radiation oncology. The study comprised retrieval of medical records for different variables like age, stage, district etc and analysing it to understand the presentation and burden of disease. Results: A total of 470 patients were studied for their epidemiology. Majority of patients were from Lucknow (78) and its nearby districts. Out of 75 districts of Uttar Pradesh, patients from 38 different districts had come to seek radiation treatment which is almost half of the Uttar Pradesh. Majority of patients in study were women in their 5th& 6th decade. The most common stage of diagnosis was II B. On histopathological evaluation most common variant found was squamous cell carcinoma with moderate differentiation 26.38%. Conclusion: Our study highlights lack of resources in Uttar Pradesh as patients had travelled from peripheral districts to seek treatment, which lead to frequent treatment breaks and poor compliance for follow up.
Aim The association of excision repair cross‐complementing 1 mRNA (ERCC‐1 mRNA) expression with the outcome has been reported with immunohistochemistry (IHC) using tumor tissue in head and neck cancer. We evaluated ERCC‐1 mRNA expression by reverse transcription polymerase chain reaction (RT‐PCR) from peripheral blood lymphocytes (PBLs) as bio‐predictor of locoregional failure (LRF) to chemoradiation (CRT) for locally advanced laryngeal squamous cell cancer (LALSCC). Methods A total of 107 male patients with LALSCC were enrolled in this prospective study. ERCC‐1 mRNA expression by PBLs was determined by RT‐PCR. Definitive CRT was delivered with 35 mg/m2 weekly cisplatin. Response Evaluation Criteria in Solid Tumor 1.1 (RECIST 1.1) were used in evaluating treatment response. The primary objective was to assess LRF. The influence of patient characteristics, treatment response, weekly cisplatin cycles, ERCC mRNA expression was determined for LRF, progression‐free survival (PFS) and overall survival (OS). Results A total of 98 patients completed definitive CRT. The median value of 2‐ΔΔCT ERCC‐1 mRNA expression was 3.9; based on which it was categorized as low and high. Correlation of ERCC‐1 expression with treatment response was insignificant (P‐ .38). With a median follow‐up of 33 months; 2‐year LRF, PFS, and OS was 63.3%, 34.7% and 79.4%. The 2‐year LRF, PFS and OS for low versus high expression were 53.1% versus 73.5% (P‐value = 0.036), 44.9% versus 24.4% (P‐value = 0.047) and 81.6% versus 77.2% (P‐value = 0.33), respectively. In multivariate analysis, ERCC‐1 expression, T‐stage, N‐stage and tumor subsite are predictive factors for LRF; T‐stage and nodal recurrence for OS; stage and treatment response for PFS. Conclusion LALSCC patient with ERCC‐1 mRNA low expression was associated with lower LRF rate, and improved PFS.
Aims: The aim of this study was to compare concurrent chemoradiation along with neoadjuvant and adjuvant chemotherapy versus concurrent chemoradiation alone in locally advanced cervical cancer regarding treatment response and toxicities. Subjects and Methods: A randomized control study was done on 116 patients with locally advanced carcinoma cervix (Stage IIB to IIIB) registered between January 2014 and February 2015. Patients were randomly divided to receive either one cycle of cisplatin/5-fluorouracil neoadjuvant chemotherapy and two cycles of the same adjuvant chemotherapy with concurrent chemoradiation with weekly cisplatin (Arm A) or only concurrent chemoradiation (Arm B). All patients received three fractions of high-dose-rate intracavitary brachytherapy after completion of the external radiation. Results: A higher proportion of the patients of chemotherapy arm achieved complete response (94%) as compared to the nonchemotherapy arm (56%), and this was statistically significant. There was a trend toward more treatment-related acute toxicity with chemotherapy. Conclusions: These results have corroborated the view that if neoadjuvant and adjuvant chemotherapies are added to concurrent chemoradiation, it could further the effects of concurrent chemoradiation for patients with locally advanced cancer of the uterine cervix.
Chemotherapy-induced peripheral neuropathy (CIPN) is a well-documented toxicity leading to dose limitation.Ibrutinib is an oral Bruton’s Tyrosine Kinase (BTK) inhibitor approved for treating chronic lymphocytic lymphoma. The most common neurological side effects of Ibrutinib include headache and dizziness. Herein, we report peripheral neuropathy as a dose-limiting manifestation of Ibrutinib treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.